Loading
Total declarations
Company
▲ Purchases (1 ops.)
▼ Sales (8 ops.)
Latest filing published 23 Jun 2026 for MoonLake Immunotherapeutics, €755k.
Filing timeline
BuySaleMatthias Bodenstedt
Insider track record
Disclosed buys
1
Disclosed sells
8
Signal history
Closed purchases
Market purchases
1
Not enough history yet: 1 closed purchase, at least 2 are needed.
Purchases by company
Since each purchase
- +39.8%Entry US$10.26 · Close at T+90 US$14.34
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Matthias Bodenstedt: trading record in brief
Matthias Bodenstedt, listed as finance chief, appears in our data through filings on MoonLake Immunotherapeutics shares, published by SEC (Form 4). We count 14 filings; the first trade dates from 5 April 2023 and the latest from 22 June 2026.
Market trades split into 1 purchase (€85k) and 8 sales (€7.9M). Netting one side against the other leaves €7.8M of net selling. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 2 share grants. Since January 2026: no purchases and 7 sales on the market.
The newest entry dates from 23 June 2026: an open-market sale of €755k, in MoonLake Immunotherapeutics. The latest purchase dates back some time: it was published 380 days ago, on 9 October 2025. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Matthias Bodenstedt
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations14 total
39,120 shares@ US$22.049.5% of flowClass A ordinary shares, par value $0.0001 per shareSEC:0001213900-26-071075:0
2,794 shares@ US$19.600.6% of flowClass A ordinary shares, par value $0.0001 per shareSEC:0001213900-26-070259:1
15,082 shares@ US$19.683.2% of flowClass A ordinary shares, par value $0.0001 per shareSEC:0001213900-26-070259:0
13,653 shares@ US$20.020.019% mcap3.4% of flowClass A ordinary shares, par value $0.0001 per shareSEC:0001213900-26-055799:0
2,426 shares@ US$19.560.0029% mcap0.6% of flowClass A ordinary shares, par value $0.0001 per shareSEC:0001213900-26-044642:0
85,870 shares@ US$18.9420.1% of flowClass A ordinary shares, par value $0.0001 per shareSEC:0001213900-26-042629:0
1,925 shares@ US$19.510.0023% mcap0.5% of flowClass A ordinary shares, par value $0.0001 per shareSEC:0001213900-26-042629:1
354,296 shares0Class A ordinary shares, par value $0.0001 per shareSEC:0001213900-26-002907:0
294,473 sharesClass A ordinary shares, par value $0.0001 per shareSEC:0001213900-25-124519:0
10,870 shares@ US$9.091.2% of flowClass A ordinary shares, par value $0.0001 per shareSEC:0001213900-25-097594:0
Canonical exit: 6 Jan 2026 (T+90)
95,763 shares0Class A ordinary shares, par value $0.0001 per shareSEC:0001213900-25-019672:0
94,736 shares@ US$59.2274.3% of flowClass A ordinary shares, par value $0.0001 per shareSEC:0001213900-23-097671:0
62,972 sharesClass A ordinary shares, par value $0.0001 per shareSEC:0001013762-23-001300:0
410,796 sharesClass A ordinary shares, par value $0.0001 per shareSEC:0001213900-23-028294:0
14 of 14 declarations
